Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-hydroxy-2-isopropylguanidine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
1-hydroxy-2-isopropylguanidine is a small molecule belonging to the class of N-hydroxyguanidines, characterized by a guanidine group with an isopropyl and hydroxy substitution. It has been studied as an experimental compound and is not approved for clinical use. Its primary mechanism of action is as an inhibitor of nitric oxide synthase 1 (NOS1), also known as neuronal nitric oxide synthase, which may modulate nitric oxide production in biological systems[1][3]. There are no approved indications or marketed formulations for this compound.
- Other names
- 1-hydroxy-2-propan-2-ylguanidineN-isopropyl-N'-hydroxyguanidine(E)-N-hydroxy-N''-(propan-2-yl)guanidine
02
Targets
NOS1 (nNOS)
Beyond the preview
Go deeper on 1-hydroxy-2-isopropylguanidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1-hydroxy-2-isopropylguanidine.